세계의 소아 성장 호르몬 결핍증(PGHD) 시장 : 산업 규모, 점유율, 동향, 성장 기회, 예측 : 유형별, 제품 유형별, 용도별, 약제별, 유통경로별, 지역별, 경쟁(2020-2030년)
Pediatric Growth Hormone Deficiency Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Type, By Product, By Application, By Drug, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1728076
리서치사:TechSci Research
발행일:2025년 05월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 소아 성장 호르몬 결핍증(PGHD) 시장은 2024년 38억 7,000만 달러로 평가되었고, 2030년에는 64억 1,000만 달러에 이를 것으로 예측되며, 예측 기간 동안 CAGR 8.77%로 성장할 전망입니다.
이 시장은 어린이의 성장 호르몬 결핍을 관리하기 위한 다양한 진단 도구와 치료 솔루션을 포함합니다. 유전적 이상, 선천적 문제, 뇌 손상, 의료 치료의 부작용 등 다양한 요인으로 인한 PGHD의 발생률이 증가함에 따라 호르몬 기반 치료에 대한 수요가 지속적으로 증가하고 있습니다. 생물공학 기술의 발전은 치료 효과와 환자 순응도를 모두 개선한 혁신적인 재조합 인간 성장 호르몬의 개발로 이어졌습니다. 특히, Pfizer와 OPKO의 주 1회 투여형 소마트로곤 주사가 2022년 EU 승인을 받으며 치료 혁신의 중요한 진전을 보여주었습니다. 또한, 합성 호르몬 치료에 대한 인식과 수용도가 증가하고, 터너 증후군과 같은 질환의 유병률이 기록적으로 증가함에 따라 시장 확대에 기여하고 있습니다. 연구 개발 활동의 증가, 지원적인 규제 환경, 맞춤형 치료제의 공급 확대는 PGHD 시장이 전 세계적으로 지속 가능한 성장을 이어갈 것으로 전망됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모(2024년)
38억 7,000만 달러
시장 규모(2030년)
64억 1,000만 달러
CAGR(2025-2030년)
8.77%
급성장 부문
성장 호르몬 결핍증
최대 시장
북미
시장 성장 촉진요인
소아 성장 호르몬 결핍증(PGHD)의 유병률 증가
주요 시장 과제
성장 호르몬 치료의 높은 비용
주요 시장 동향
생물학적 및 바이오시밀러 성장 호르몬 치료법
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 소아 성장 호르몬 결핍증 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
유형별(선천성 GH 결핍증, 후천성 GH 결핍증, 특발성 GH 결핍증)
제품 유형별(분말, 용매)
용도별(성장 호르몬 결핍증, 특발성 저신장증, 터너 증후군, 임신 주수에 비해 작은 신장, 프라더-윌리 증후군, 기타)
약제별(제노트로핀, 휴머트로프, 노르디트로핀 플렉스 프로, 기타)
유통 경로별(병원 약국, 소매 약국, 온라인 약국, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 소아 성장 호르몬 결핍증 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 소아 성장 호르몬 결핍증 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 소아 성장 호르몬 결핍증 시장 전망
시장 규모와 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 소아 성장 호르몬 결핍증 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 소아 성장 호르몬 결핍증 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
합병과 인수
제13장 세계의 소아 성장 호르몬 결핍증 시장 : SWOT 분석
제14장 경쟁 구도
Novo Nordisk A/S
Eli Lily and Company
Novartis AG
Merck KgaA
Pfizer Inc.
Ferring BV
Genentech Inc
BioParteners GmbH
LG Chem Ltd.
Ipsen Pharma
제15장 전략적 제안
제16장 기업 소개와 면책사항
HBR
영문 목차
영문목차
The Global Pediatric Growth Hormone Deficiency (PGHD) Market was valued at USD 3.87 billion in 2024 and is projected to reach USD 6.41 billion by 2030, growing at a CAGR of 8.77% during the forecast period. This market encompasses a wide range of diagnostic tools and therapeutic solutions aimed at managing growth hormone deficiency in children. The rising incidence of PGHD, caused by factors such as genetic abnormalities, congenital issues, brain trauma, and side effects of medical treatments, continues to increase demand for hormone-based therapies. Advancements in biotechnology have led to the development of innovative recombinant human growth hormones, improving both treatment efficacy and patient compliance. Notably, Pfizer and OPKO's once-weekly somatrogon injection received EU approval in 2022, reflecting a significant stride in therapeutic innovation. Moreover, increasing awareness and acceptance of synthetic hormone therapy, alongside the documented prevalence of conditions like Turner Syndrome, further contribute to the market's expansion. Growing R&D activity, combined with a supportive regulatory environment and targeted treatment availability, positions the PGHD market for sustained growth globally.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 3.87 Billion
Market Size 2030
USD 6.41 Billion
CAGR 2025-2030
8.77%
Fastest Growing Segment
Growth Hormone Deficiency
Largest Market
North America
Key Market Drivers
Increasing Prevalence of Pediatric Growth Hormone Deficiency (PGHD)
The rising number of pediatric growth hormone deficiency cases is a major growth driver for the global PGHD market. This increase is largely attributable to genetic predispositions, premature births, and improved diagnostic capabilities. Children born with a family history of GHD or with low birth weight are more prone to hormonal imbalances, prompting early screening and treatment. Enhanced neonatal care has also improved survival rates of premature infants, many of whom later require hormonal support for growth. Additionally, broader access to genetic testing and heightened medical surveillance has led to earlier diagnosis and a higher number of treated cases. As awareness around PGHD grows, healthcare providers and caregivers are more proactive in seeking timely intervention, contributing to rising treatment demand.
Key Market Challenges
High Cost of Growth Hormone Therapy
The significant cost associated with growth hormone therapy remains a key challenge for market growth. These treatments often involve long-term regimens with regular injections, which can accumulate substantial expenses for families. In regions with limited insurance coverage or insufficient healthcare infrastructure, the affordability of such therapies becomes a major barrier. The high treatment cost can also deter therapy initiation or result in poor adherence, ultimately impacting patient outcomes and limiting market expansion, particularly in low- and middle-income countries.
Key Market Trends
Biological and Biosimilar Growth Hormone Therapies
A notable trend shaping the PGHD market is the increased adoption of biological and biosimilar hormone therapies. Biological products, produced using living cells, offer high specificity and therapeutic precision, while biosimilars provide a cost-effective alternative with similar clinical efficacy. The growing entry of biosimilars into the market has fostered greater competition, resulting in improved affordability and access. As biosimilars become more widely accepted, healthcare providers can tailor treatment regimens with a broader portfolio of therapeutic options, making hormone replacement therapy more accessible and personalized.
Key Market Players
Novo Nordisk A/S
Eli Lily and Company
Novartis AG
Merck KgaA
Pfizer Inc.
Ferring B.V
Genentech Inc
BioParteners GmbH
LG Chem Ltd.
Ipsen Pharma
Report Scope:
In this report, the Global Pediatric Growth Hormone Deficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Pediatric Growth Hormone Deficiency Market, By Type:
Congenital GH Deficiency
Acquired GH Deficiency
Idiopathic GH Deficiency
Pediatric Growth Hormone Deficiency Market, By Product:
Powder
Solvent
Pediatric Growth Hormone Deficiency Market, By Application:
Growth Hormone Deficiency
Idiopathic Short Stature
Turner Syndrome
Small For Gestational Age
Prader-Willi Syndrome
Others
Pediatric Growth Hormone Deficiency Market, By Drug:
Genotropin
Humatrope
Norditropin FlexPro
Others
Pediatric Growth Hormone Deficiency Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Pediatric Growth Hormone Deficiency Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Turkey
Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Growth Hormone Deficiency Market.
Available Customizations:
Global Pediatric Growth Hormone Deficiency market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Applications
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Pediatric Growth Hormone Deficiency Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Congenital GH Deficiency, Acquired GH Deficiency, Idiopathic GH Deficiency)
5.2.2. By Product (Powder, Solvent)
5.2.3. By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome, Others)
5.2.4. By Drug (Genotropin, Humatrope, Norditropin Flexpro, Others)
5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America Pediatric Growth Hormone Deficiency Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Product
6.2.3. By Application
6.2.4. By Drug
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Pediatric Growth Hormone Deficiency Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Product
6.3.1.2.3. By Application
6.3.1.2.4. By Drug
6.3.1.2.5. By Distribution Channel
6.3.2. Canada Pediatric Growth Hormone Deficiency Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Product
6.3.2.2.3. By Application
6.3.2.2.4. By Drug
6.3.2.2.5. By Distribution Channel
6.3.3. Mexico Pediatric Growth Hormone Deficiency Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Product
6.3.3.2.3. By Application
6.3.3.2.4. By Drug
6.3.3.2.5. By Distribution Channel
7. Europe Pediatric Growth Hormone Deficiency Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Product
7.2.3. By Application
7.2.4. By Drug
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pediatric Growth Hormone Deficiency Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Product
7.3.1.2.3. By Application
7.3.1.2.4. By Drug
7.3.1.2.5. By Distribution Channel
7.3.2. United Kingdom Pediatric Growth Hormone Deficiency Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Product
7.3.2.2.3. By Application
7.3.2.2.4. By Drug
7.3.2.2.5. By Distribution Channel
7.3.3. Italy Pediatric Growth Hormone Deficiency Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Type
7.3.3.2.2. By Product
7.3.3.2.3. By Application
7.3.3.2.4. By Drug
7.3.3.2.5. By Distribution Channel
7.3.4. France Pediatric Growth Hormone Deficiency Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Product
7.3.4.2.3. By Application
7.3.4.2.4. By Drug
7.3.4.2.5. By Distribution Channel
7.3.5. Spain Pediatric Growth Hormone Deficiency Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Product
7.3.5.2.3. By Application
7.3.5.2.4. By Drug
7.3.5.2.5. By Distribution Channel
8. Asia-Pacific Pediatric Growth Hormone Deficiency Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Product
8.2.3. By Application
8.2.4. By Drug
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Pediatric Growth Hormone Deficiency Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Product
8.3.1.2.3. By Application
8.3.1.2.4. By Drug
8.3.1.2.5. By Distribution Channel
8.3.2. India Pediatric Growth Hormone Deficiency Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Product
8.3.2.2.3. By Application
8.3.2.2.4. By Drug
8.3.2.2.5. By Distribution Channel
8.3.3. Japan Pediatric Growth Hormone Deficiency Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Product
8.3.3.2.3. By Application
8.3.3.2.4. By Drug
8.3.3.2.5. By Distribution Channel
8.3.4. South Korea Pediatric Growth Hormone Deficiency Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Product
8.3.4.2.3. By Application
8.3.4.2.4. By Drug
8.3.4.2.5. By Distribution Channel
8.3.5. Australia Pediatric Growth Hormone Deficiency Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Product
8.3.5.2.3. By Application
8.3.5.2.4. By Drug
8.3.5.2.5. By Distribution Channel
9. South America Pediatric Growth Hormone Deficiency Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Product
9.2.3. By Application
9.2.4. By Drug
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pediatric Growth Hormone Deficiency Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Product
9.3.1.2.3. By Application
9.3.1.2.4. By Drug
9.3.1.2.5. By Distribution Channel
9.3.2. Argentina Pediatric Growth Hormone Deficiency Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Product
9.3.2.2.3. By Application
9.3.2.2.4. By Drug
9.3.2.2.5. By Distribution Channel
9.3.3. Colombia Pediatric Growth Hormone Deficiency Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Product
9.3.3.2.3. By Application
9.3.3.2.4. By Drug
9.3.3.2.5. By Distribution Channel
10. Middle East and Africa Pediatric Growth Hormone Deficiency Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Product
10.2.3. By Application
10.2.4. By Drug
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pediatric Growth Hormone Deficiency Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Product
10.3.1.2.3. By Application
10.3.1.2.4. By Drug
10.3.1.2.5. By Distribution Channel
10.3.2. Saudi Arabia Pediatric Growth Hormone Deficiency Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Product
10.3.2.2.3. By Application
10.3.2.2.4. By Drug
10.3.2.2.5. By Distribution Channel
10.3.3. UAE Pediatric Growth Hormone Deficiency Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Product
10.3.3.2.3. By Application
10.3.3.2.4. By Drug
10.3.3.2.5. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challanges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Pediatric Growth Hormone Deficiency Market: SWOT Analysis
